Xenon Pharmaceuticals (XENE) Competitors $32.26 +0.10 (+0.31%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$32.26 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XENE vs. BPMC, ROIV, RVMD, BBIO, ELAN, VRNA, LEGN, TGTX, GRFS, and LNTHShould you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma (VRNA), Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Xenon Pharmaceuticals vs. Its Competitors Blueprint Medicines Roivant Sciences Revolution Medicines BridgeBio Pharma Elanco Animal Health Verona Pharma Legend Biotech TG Therapeutics Grifols Lantheus Xenon Pharmaceuticals (NASDAQ:XENE) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking. Do institutionals and insiders believe in XENE or BPMC? 95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. 5.5% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, XENE or BPMC? Xenon Pharmaceuticals has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Do analysts recommend XENE or BPMC? Xenon Pharmaceuticals currently has a consensus price target of $54.82, suggesting a potential upside of 69.93%. Blueprint Medicines has a consensus price target of $129.35, suggesting a potential upside of 1.10%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Xenon Pharmaceuticals is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00Blueprint Medicines 0 Sell rating(s) 16 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.32 Does the media prefer XENE or BPMC? In the previous week, Blueprint Medicines had 9 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 18 mentions for Blueprint Medicines and 9 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.95 beat Blueprint Medicines' score of 0.56 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Blueprint Medicines 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is XENE or BPMC more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. Xenon Pharmaceuticals' return on equity of -24.69% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Xenon PharmaceuticalsN/A -24.69% -23.68% Blueprint Medicines -13.19%-77.49%-20.84% Which has stronger valuation & earnings, XENE or BPMC? Blueprint Medicines has higher revenue and earnings than Xenon Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenon Pharmaceuticals$7.50M330.06-$182.39M-$3.23-9.99Blueprint Medicines$562.12M14.70-$67.09M-$2.47-51.80 Does the MarketBeat Community favor XENE or BPMC? Blueprint Medicines received 122 more outperform votes than Xenon Pharmaceuticals when rated by MarketBeat users. However, 69.79% of users gave Xenon Pharmaceuticals an outperform vote while only 66.99% of users gave Blueprint Medicines an outperform vote. CompanyUnderperformOutperformXenon PharmaceuticalsOutperform Votes43269.79% Underperform Votes18730.21% Blueprint MedicinesOutperform Votes55466.99% Underperform Votes27333.01% SummaryXenon Pharmaceuticals beats Blueprint Medicines on 12 of the 19 factors compared between the two stocks. Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XENE vs. The Competition Export to ExcelMetricXenon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.48B$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-11.448.7827.1720.06Price / Sales330.06255.64410.88157.10Price / CashN/A65.8538.2534.64Price / Book2.286.557.094.70Net Income-$182.39M$143.93M$3.23B$247.88M7 Day Performance4.98%3.97%2.91%2.66%1 Month Performance-10.01%11.32%9.09%6.40%1 Year Performance-15.90%4.20%31.75%14.07% Xenon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XENEXenon Pharmaceuticals3.5091 of 5 stars$32.26+0.3%$54.82+69.9%-15.0%$2.48B$7.50M-11.44210Options VolumeAnalyst RevisionHigh Trading VolumeBPMCBlueprint Medicines1.1811 of 5 stars$127.97+0.1%$129.35+1.1%+21.4%$8.26B$562.12M-118.49640High Trading VolumeROIVRoivant Sciences2.3781 of 5 stars$11.08-1.3%$17.50+57.9%+6.7%$7.91B$29.05M-73.86860RVMDRevolution Medicines4.4448 of 5 stars$40.58-1.2%$67.08+65.3%+4.5%$7.56B$742K-11.30250Positive NewsBBIOBridgeBio Pharma4.6128 of 5 stars$39.03+1.1%$57.36+47.0%+42.1%$7.41B$127.42M-13.69400Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionGap UpELANElanco Animal Health1.4106 of 5 stars$13.94+0.3%$15.17+8.8%-22.3%$6.92B$4.43B34.859,800VRNAVerona Pharma2.5029 of 5 stars$84.64+0.4%$82.13-3.0%+573.5%$6.86B$118.54M-44.0830Trending NewsAnalyst ForecastAnalyst RevisionLEGNLegend Biotech3.1066 of 5 stars$34.78-0.6%$76.20+119.1%-17.3%$6.39B$728.30M-36.611,070Trending NewsShort Interest ↑Analyst RevisionTGTXTG Therapeutics2.7751 of 5 stars$39.84-0.5%$40.80+2.4%+137.3%$6.32B$386.39M-398.36290Positive NewsAnalyst RevisionGRFSGrifols3.6544 of 5 stars$8.83+0.1%N/A+28.4%$6.07B$7.21B7.5526,300LNTHLantheus4.4964 of 5 stars$83.22+2.0%$132.67+59.4%-0.4%$5.76B$1.54B13.85700 Related Companies and Tools Related Companies Blueprint Medicines Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Verona Pharma Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives Grifols Alternatives Lantheus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XENE) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XENE Stock Free XENE Stock Alerts